A Small Change Can Make a Big Difference: A Lesson from Evolocumab

Sam Mirzaee, Paul M. Thein, Dennis Wong, Arthur Nasis

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Background: Evolocumab is an expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes in high risk patients. Methods: This is a case study describing a stepwise approach to “PCSK9 inhibitor non-response” in a patient with familial hypercholesterolaemia. There are a few described pathophysiological mechanisms for “PCSK9 inhibitor non-response” including homozygous LDL-C receptor-negative mutations and alteration in the binding site of PCSK9 inhibitors. Results: We report the case of a 41-year-old woman with familial hypercholesterolaemia and premature cardiovascular disease, who was non-responsive to the action of PCSK9 inhibitor solely due to the incorrect subcutaneous injection technique. Conclusions: This case study highlights the importance of reviewing the accuracy of SC injection technique in patients with minimal or no response to PCSK9 inhibitors prior to proceeding to costly genetic testing.

Original languageEnglish
Pages (from-to)e21–e22
Number of pages2
JournalHeart Lung and Circulation
Volume28
DOIs
Publication statusPublished - Mar 2019

Keywords

  • Coronary artery disease
  • Evolocumab
  • Familial hypercholesterolaemia
  • PCSK9 inhibitor

Cite this

@article{15be69cd69934361a54ebf9c7a493064,
title = "A Small Change Can Make a Big Difference: A Lesson from Evolocumab",
abstract = "Background: Evolocumab is an expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes in high risk patients. Methods: This is a case study describing a stepwise approach to “PCSK9 inhibitor non-response” in a patient with familial hypercholesterolaemia. There are a few described pathophysiological mechanisms for “PCSK9 inhibitor non-response” including homozygous LDL-C receptor-negative mutations and alteration in the binding site of PCSK9 inhibitors. Results: We report the case of a 41-year-old woman with familial hypercholesterolaemia and premature cardiovascular disease, who was non-responsive to the action of PCSK9 inhibitor solely due to the incorrect subcutaneous injection technique. Conclusions: This case study highlights the importance of reviewing the accuracy of SC injection technique in patients with minimal or no response to PCSK9 inhibitors prior to proceeding to costly genetic testing.",
keywords = "Coronary artery disease, Evolocumab, Familial hypercholesterolaemia, PCSK9 inhibitor",
author = "Sam Mirzaee and Thein, {Paul M.} and Dennis Wong and Arthur Nasis",
year = "2019",
month = "3",
doi = "10.1016/j.hlc.2018.03.009",
language = "English",
volume = "28",
pages = "e21–e22",
journal = "Heart Lung and Circulation",
issn = "1443-9506",
publisher = "Elsevier",

}

A Small Change Can Make a Big Difference : A Lesson from Evolocumab. / Mirzaee, Sam; Thein, Paul M.; Wong, Dennis; Nasis, Arthur.

In: Heart Lung and Circulation, Vol. 28, 03.2019, p. e21–e22.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - A Small Change Can Make a Big Difference

T2 - A Lesson from Evolocumab

AU - Mirzaee, Sam

AU - Thein, Paul M.

AU - Wong, Dennis

AU - Nasis, Arthur

PY - 2019/3

Y1 - 2019/3

N2 - Background: Evolocumab is an expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes in high risk patients. Methods: This is a case study describing a stepwise approach to “PCSK9 inhibitor non-response” in a patient with familial hypercholesterolaemia. There are a few described pathophysiological mechanisms for “PCSK9 inhibitor non-response” including homozygous LDL-C receptor-negative mutations and alteration in the binding site of PCSK9 inhibitors. Results: We report the case of a 41-year-old woman with familial hypercholesterolaemia and premature cardiovascular disease, who was non-responsive to the action of PCSK9 inhibitor solely due to the incorrect subcutaneous injection technique. Conclusions: This case study highlights the importance of reviewing the accuracy of SC injection technique in patients with minimal or no response to PCSK9 inhibitors prior to proceeding to costly genetic testing.

AB - Background: Evolocumab is an expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor which has been shown to significantly improve cardiovascular outcomes in high risk patients. Methods: This is a case study describing a stepwise approach to “PCSK9 inhibitor non-response” in a patient with familial hypercholesterolaemia. There are a few described pathophysiological mechanisms for “PCSK9 inhibitor non-response” including homozygous LDL-C receptor-negative mutations and alteration in the binding site of PCSK9 inhibitors. Results: We report the case of a 41-year-old woman with familial hypercholesterolaemia and premature cardiovascular disease, who was non-responsive to the action of PCSK9 inhibitor solely due to the incorrect subcutaneous injection technique. Conclusions: This case study highlights the importance of reviewing the accuracy of SC injection technique in patients with minimal or no response to PCSK9 inhibitors prior to proceeding to costly genetic testing.

KW - Coronary artery disease

KW - Evolocumab

KW - Familial hypercholesterolaemia

KW - PCSK9 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85045731998&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2018.03.009

DO - 10.1016/j.hlc.2018.03.009

M3 - Article

VL - 28

SP - e21–e22

JO - Heart Lung and Circulation

JF - Heart Lung and Circulation

SN - 1443-9506

ER -